Curis, Inc. earnings releases CRIS

Annual Quarterly

Curis, Inc. last reported quarterly results on May 12, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): revenue of $0 (-100.0% year over year) and diluted EPS of -$1.25. It usually reports 36–42 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–42 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
May 12, 2026 42 days after quarter end	Q1 FY2026 ended Mar 31, 2026	0 -100.0%	-24 -127.9%	-1.25 +0.0%
Nov 6, 2025 37 days after quarter end	Q3 FY2025 ended Sep 30, 2025	3 +8.4%	-8 +23.4%	-0.49 +71.2%
Aug 5, 2025 36 days after quarter end	Q2 FY2025 ended Jun 30, 2025	3 +8.0%	-9 +27.2%	-13.61 -570.4%
May 6, 2025 36 days after quarter end	Q1 FY2025 ended Mar 31, 2025	2 +14.1%	-11 +10.6%	-1.25 +39.0%
Nov 14, 2024 45 days after quarter end	Q3 FY2024 ended Sep 30, 2024	3 +3.5%	-10 +17.1%	-1.70 +20.2%
Aug 1, 2024 32 days after quarter end	— ended Jun 30, 2024	—	—	—
May 7, 2024 37 days after quarter end	— ended Mar 31, 2024	—	—	—
Feb 8, 2024 39 days after quarter end	— ended Dec 31, 2023	—	—	—

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: CRIS (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Lexington, MA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1108205

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.